1 Recommendations

Sr.no.	Recommendations	SoR	QoE
1	The AGA recommends using linaclotide (over no drug treatment) in patients with IBS-C. Comments: Patients who place a high value on avoiding diarrhea and avoiding higher out-of-pocket expenses associated with linaclotide may prefer alternate treatments.	Strong	High
Evidence for Recommendation 1
2	The AGA suggests using lubiprostone (over no drug treatment) in patients with IBS-C. Comments: Patients who place a high value on avoiding higher out-of-pocket expenses associated with lubiprostone may prefer alternate treatments.	Cond	Mod
Evidence for Recommendation 2
3	The AGA suggests using laxatives (over no drug treatment) in patients with IBS-C.	Cond	Low
Evidence for Recommendation 3
4	The AGA suggests using rifaximin (over no drug treatment) in patients with IBS-D.	Cond	Mod
Evidence for Recommendation 4
5	The AGA suggests using alosetron (over no drug treatment) in patients with IBS-D to improve global symptoms.	Cond	Mod
Evidence for Recommendation 5
6	The AGA suggests using loperamide (over no drug treatment) in patients with IBS-D.	Cond	V Low
Evidence for Recommendation 6
7	The AGA suggests using tricyclic antidepressants (over no drug treatment) in patients with IBS.	Cond	Low
Evidence for Recommendation 7
8	The AGA suggests against using selective serotonin reuptake inhibitors for patients with IBS.	Cond	Low
Evidence for Recommendation 8
9	The AGA suggests using antispasmodics (over no drug treatment) in patients with IBS.	Cond	Low
Evidence for Recommendation 9

SoR: Strength of Recommendation
QoE: Quality of Evidence
Strong: Strong Recommendation
Cond: Conditional Recommendation
High: High-Quality Evidence
Mod: Moderate-Quality Evidence
Low: Low-Quality Evidence
V Low: Very Low-Quality Evidence
AGA: American Gastroenterological Association
IBS: Irritable bowel syndrome
IBS-C: Irritable bowel syndrome with constipation
IBS-D: Irritable bowel syndrome with diarrhea